Rezilient Health operates CloudClinics that connect patients with physicians using remote digital diagnostic tools for primary care, specialty care, and in-house labs, plus 24/7 messaging. The company emphasizes value-based care and aims to reduce employers’ total cost of care by increasing access and utilization of those services. Led by CEO and Co‑Founder Dr. Danish Nagda and COO and Co‑Founder Jeff Gamble, PhD, Rezilient combines clinical care with digital tools to deliver concierge-style services. The company intends to use new funding to expand its scope of services and bring concierge healthcare to more people regardless of economic status. Financially, Rezilient closed a $10M Series A in March 2024 to support that expansion. The business model targets employer-sponsored care and broader access through its tech-enabled clinic footprint. Rezilient Health operates membership-based CloudClinics that combine physical, strategically located spaces with connected diagnostic systems and an advanced video platform so doctors can deliver remote primary care. When patients arrive, a nurse facilitates vitals, labs, and physical exam elements while physicians appear on a monitor and control integrated digital devices to listen to hearts or examine eardrums in real time. The Rezilient app guides patients to same-day appointments, enables telehealth follow-ups, and the average appointment length is about 30 minutes. The service is accepted by major insurers including Aetna, Blue Cross Blue Shield, Cigna, Humana, and UnitedHealthcare. Founded in 2016 by Danish Nagada, MD and Jeff Gamble, Ph.D., the company is based in St. Louis and plans to expand its engineering and software development teams and roll out CloudClinics in the St. Louis area. Rezilient is launching its first CloudClinics with major employers in fall 2021 offering primary care, urgent care, and mental healthcare, and a national rollout is slated for 2022. The company recently closed an oversubscribed $2.5M seed round to support these efforts.

Total raised

$13M

Funding rounds

2

Latest round

Series A

Latest activity

Oct 2024